Ampliphi Biosciences Corp (NASDAQ:APHB) has been given a $5.00 price objective by equities researchers at HC Wainwright in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 410.20% from the stock’s previous close.

Shares of Ampliphi Biosciences Corp (NASDAQ:APHB) opened at 0.98 on Monday. Ampliphi Biosciences Corp has a 52 week low of $0.67 and a 52 week high of $16.90. The stock’s market capitalization is $8.57 million. The stock has a 50 day moving average price of $0.85 and a 200 day moving average price of $1.08.

Ampliphi Biosciences Corp (NASDAQ:APHB) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.02. Ampliphi Biosciences Corp had a negative net margin of 23,075.00% and a negative return on equity of 313.95%. The company had revenue of $0.03 million during the quarter. On average, equities research analysts expect that Ampliphi Biosciences Corp will post ($2.87) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Ampliphi Biosciences Corp (APHB) PT Set at $5.00 by HC Wainwright” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/04/ampliphi-biosciences-corp-aphb-pt-set-at-5-00-by-hc-wainwright.html.

A hedge fund recently raised its stake in Ampliphi Biosciences Corp stock. Sabby Management LLC grew its holdings in shares of Ampliphi Biosciences Corp (NASDAQ:APHB) by 139.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 731,409 shares of the company’s stock after purchasing an additional 426,490 shares during the period. Sabby Management LLC owned approximately 8.36% of Ampliphi Biosciences Corp worth $570,000 as of its most recent SEC filing.

About Ampliphi Biosciences Corp

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Stock Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related stocks with our FREE daily email newsletter.